MedPath

Effect of inhaler salbutamol versus placebo on treatment of neonatal transient tachypnea

Phase 2
Recruiting
Conditions
eonatal transient tachypnea.
Transient tachypnoea of newborn
Registration Number
IRCT201711139014N201
Lead Sponsor
Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
52
Inclusion Criteria

Age of 34 to 47 weeks; neonatal transient tachypnea.
Exclusion criteria: Pneumothorax; maternal addiction; respiratory distress syndrome; meconium aspiration; pneumonia; sepsis; congenital heart disease; pulmonary hypertension.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of breathing. Timepoint: Before and 0.5, 1 and 4 hours after treatment. Method of measurement: By physical examination.;TTN clinical score. Timepoint: Before and 0.5, 1 and 4 hours after treatment. Method of measurement: By physical examination.;Arterial oxygen saturation. Timepoint: Before and 4 hours after treatment. Method of measurement: By checking arterial blood sample.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath